OREANDA-NEWS. Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, reported financial results for the three and six months ended June 30, 2016.

Revenues for the three and six months ended June 30, 2016 were $26.1 million and $53.1 million, respectively.  Loss per diluted share, as measured under U.S. generally accepted accounting principles (“GAAP”), for the three and six months ended June 30, 2016 was $0.02 and $0.04, respectively, while earnings per diluted share, on a non-GAAP basis, was $0.03 and $0.08, respectively, for the same periods.

Jeffrey Duchemin, President and CEO of Harvard Bioscience, said, “At the half way point of fiscal year 2016, we remain confident in achieving our financial objectives and goals for the year.  Our second quarter results reflect some near term challenges faced in the quarter.  We believe the most challenging time of the year is behind us and our results will benefit from a few tailwinds in the second half of the year.  For one, our former GE spectrophotometer business, which was negatively impacted by GE’s decision to discontinue sales in the second half of 2015, continues to ramp up and will be up side for us for the remaining six months of the year as compared to the same periods in 2015.  We continue to be pleased with our progress as we develop this direct channel since taking over the sales and service of NanoVue and SimpliNano spectrophotometers on January 1, 2016.”

“Overall, we remain steadfast in our commitment to our strategic priorities and the shareholder value we believe it creates.  We are positioned to finish the year strongly through commercial and operational execution.”

Second Quarter Reported Results

  • Revenues for the three months ended June 30, 2016 were $26.1 million, a decrease of approximately $2.7 million, or 9% compared to revenues of $28.8 million for the three months ended June 30, 2015. Excluding currency translation, revenues decreased 9% or $2.5 million. For a reconciliation of changes in revenues, refer to Exhibit 8 below.
     
  • Net loss, as measured under U.S. generally accepted accounting principles (“GAAP”), was $0.7 million, or $0.02 per diluted share, for the three months ended June 30, 2016 compared to net income of $0.3 million, or $0.01 per diluted share, for the same quarter in 2015.
     
  • Net income, on a non-GAAP basis, was $1.0 million, or $0.03 per diluted share, for the three months ended June 30, 2016, compared to $1.6 million, or $0.05 per diluted share, for the three months ended June 30, 2015. For a reconciliation between GAAP and non-GAAP net income, and between GAAP and non-GAAP diluted earnings per share, refer to Exhibits 5 and 6 below, respectively. Additionally, refer to Exhibit 9 for the non-GAAP consolidated statement of operations. 

Year-to-Date Reported Results

  • Revenues for the six months ended June 30, 2016 were $53.1 million, a decrease of approximately $1.5 million, or 3% compared to revenues of $54.6 million for the six months ended June 30, 2015. Excluding currency translation, revenues decreased 2% or $0.9 million. For a reconciliation of changes in revenues, refer to Exhibit 8 below.     
     
  • Net loss, as measured under GAAP, was $1.3 million, or $0.04 per diluted share, for the six months ended June 30, 2016 compared to $1.1 million, or $0.03 per diluted share, for the six months ended June 30, 2015.
     
  • Net income, on a non-GAAP basis, was $2.6 million, or $0.08 per diluted share, for the six months ended June 30, 2016 compared to $2.3 million, or $0.07 per diluted share, for the same period in 2015. For a reconciliation between GAAP and non-GAAP net income, and between GAAP and non-GAAP diluted earnings per share, refer to Exhibits 5 and 6 below, respectively. Additionally, refer to Exhibit 9 for the non-GAAP consolidated statement of operations.

Financial Guidance

Today we are updating our full-year 2016 financial guidance, as issued on April 29, 2016, to reflect current foreign currency exchange rates, including the impact of Brexit uncertainty on current British pound sterling rates.  We now expect to report revenues of approximately $108 million to $110 million.

On the bottom-line, we now expect to report full-year 2016 GAAP diluted earnings per share of approximately $0.00 to $0.02 and non-GAAP diluted earnings per share of $0.16 to $0.18, or a 23% to 38% increase compared to 2015 non-GAAP diluted earnings per share.

The Company may incur charges, realize gains, or experience other events in 2016 that could cause actual results to vary from this guidance. Refer to Exhibit 7 below for a reconciliation between the GAAP and non-GAAP diluted earnings per share guidance.

Conference Call Details
                       
Harvard Bioscience will be hosting a conference call and webcast today at 8:30 am ET. On that call, management may respond to questions from the audience and provide information on any of a number of topics related to the business, including operations, plans and outlook.

Participating in the call will be Jeffrey A. Duchemin, President and Chief Executive Officer and Robert Gagnon, Chief Financial Officer of Harvard Bioscience. Investors can access the live conference call by dialing the following phone numbers: toll-free 1-800-708-4540, or international: 1-847-619-6397, and referencing the conference ID# 43011203.

The conference will be simultaneously webcast and can be accessed through the Harvard Bioscience website. To listen to the webcast, log on to the webcast at http://investor.harvardbioscience.com/ and click on the Earnings Call icon. Financial information presented on the call, including the earnings release, will also be available on the investor relations section of the website.

If you are unable to listen to the live conference call, the webcast will be available on the Company's website through August 4, 2016.

Use of Non-GAAP Financial Information

In this press release, we have included non-GAAP financial information including revenues, adjusted operating income, adjusted net income and adjusted earnings per diluted share. We believe that this non-GAAP financial information provides investors with an enhanced understanding of the underlying operations of the business. For the periods presented, these non-GAAP financial measures of revenues and income have excluded certain revenues and expenses and income primarily resulting from purchase accounting or events that we do not believe are related to the underlying operations of the business such as currency translation, amortization of intangibles related to acquisitions, costs related to acquisition initiatives, forensic investigation costs, severance and restructuring expenses and stock-based compensation expense. They also exclude the tax impact of the reconciling items. This non-GAAP financial information approximates information used by our management to internally evaluate the operating results of the Company. Tabular reconciliations of our non-GAAP adjusted operating income, non-GAAP adjusted net income and non-GAAP adjusted earnings per diluted share for the three and six months ended June 30, 2016 and 2015 are included as exhibits below in this press release.

The non-GAAP financial information provided in this press release should be considered in addition to, not as a substitute for, the financial information provided and presented in accordance with GAAP.

About Harvard Bioscience

Harvard Bioscience is a global developer, manufacturer and marketer of a broad range of solutions to advance life science. Our products are sold to thousands of researchers in over 100 countries through our global sales organization, websites, catalogs, and through distributors including Thermo Fisher Scientific Inc., VWR, and other specialized distributors. 

Exhibit 1        
HARVARD BIOSCIENCE, INC.
Condensed Consolidated Balance Sheet Information
(unaudited, in thousands)
         
         
    June 30,   December 31,
      2016       2015  
Assets        
         
  Cash and cash equivalents   $ 3,631     $ 6,744  
  Trade receivables     16,347       17,547  
  Inventories      22,209       22,343  
  Property, plant and equipment     5,641       5,902  
  Goodwill and other intangibles     60,577       62,452  
  Other assets     5,680       5,062  
  Total assets   $ 114,085     $ 120,050  
         
Liabilities and Stockholders' Equity        
         
  Total current liabilities   $ 14,850     $ 19,323  
  Total liabilities     37,422       42,452  
  Stockholders’ equity     76,663       77,598  
  Total liabilities and stockholders’ equity   $ 114,085     $ 120,050  
Exhibit 2                        
HARVARD BIOSCIENCE, INC.  
Consolidated Statements of Operations  
(In thousands, except per share data)  
(unaudited)  
                                       
                  Three Months Ended     Six Months Ended  
                  June 30,     June 30,  
                    2016         2015         2016         2015    
                                       
Revenues   $ 26,136       $ 28,800       $ 53,099       $ 54,563    
Cost of revenues     14,461         16,205         28,479         30,490    
  Gross profit     11,675         12,595         24,620         24,073    
                                       
Sales and marketing expenses     5,086         5,128         10,188         10,327    
General and administrative expenses     5,236         4,922         11,184         9,753    
Research and development expenses     1,502         1,714         2,927         3,462    
Restructuring charges     1         54         12         111    
Amortization of intangible assets     690         678         1,370         1,471    
  Total operating expenses     12,515         12,496         25,681         25,124    
                                       
Operating (loss) income     (840 )       99         (1,061 )       (1,051 )  
                                       
Other income (expense):                        
  Foreign exchange     282         (134 )       273         89    
  Interest expense     (180 )       (215 )       (344 )       (437 )  
  Interest income     -         3         1         4    
  Other expense, net     (29 )       (180 )       (79 )       (796 )  
Other income (expense), net     73         (526 )       (149 )       (1,140 )  
                                       
Loss before income taxes     (767 )       (427 )       (1,210 )       (2,191 )  
Income tax (benefit) expense     (54 )       (776 )       139         (1,139 )  
Net (loss) income   $ (713 )     $ 349       $ (1,349 )     $ (1,052 )  
                                       
(Loss) earnings per share:                        
  Basic (loss) earnings per common share   $ (0.02 )     $ 0.01       $ (0.04 )     $ (0.03 )  
                                       
  Diluted (loss) earnings per common share   $ (0.02 )     $ 0.01       $ (0.04 )     $ (0.03 )  
                                       
Weighted average common shares:                        
  Basic     34,127         33,569         34,070         33,240    
                                       
  Diluted     34,127         35,026         34,070         33,240    
Exhibit 3          
HARVARD BIOSCIENCE, INC.
Condensed Cash Flow Information
(unaudited, in thousands)
           
    Six Months Ended
    June 30,
      2016         2015  
           
Cash flows from operations:          
Net loss   $ (1,349 )     $ (1,052 )
Changes in assets and liabilities     (2,377 )       (2,402 )
Other adjustments to operating cash flows     3,942         2,473  
Net cash provided by (used in) operating activities     216         (981 )
           
Investing activities:          
Acquisitions, net of cash acquired     -         (4,545 )
Other investing activities     (412 )       (1,625 )
Net cash used in investing activities     (412 )       (6,170 )
           
Financing activities:          
Proceeds from issuance of debt     2,000         4,050  
Repayments of debt     (4,625 )       (4,850 )
Other financing activities     (9 )       1,832  
Net cash (used in) provided by financing activities     (2,634 )       1,032  
           
Effect of exchange rate changes on cash     (283 )       (613 )
           
Decrease in cash and cash equivalents   $ (3,113 )     $ (6,732 )
Exhibit 4  
HARVARD BIOSCIENCE, INC.  
Reconciliation of GAAP Operating (Loss) Income to Non-GAAP Adjusted Operating Income  
(unaudited, in thousands)  
                       
  Three Months Ended     Six Months Ended  
  June 30,     June 30,  
    2016         2015         2016         2015    
                       
GAAP operating (loss) income $ (840 )     $ 99       $ (1,061 )     $ (1,051 )  
                       
Adjustments:                      
                       
Amortization of intangible assets   690         678         1,370         1,471    
                       
Inventory valuation step-up charges on acquisition   -         402         -         793    
                       
Forensic investigation costs   498         -         1,663         -    
                       
Severance and restructuring charges   1         437         12         783    
                       
Stock-based compensation expense   899         692         1,653         1,272    
                       
Non-GAAP adjusted operating income $ 1,248       $ 2,308       $ 3,637       $ 3,268    
Exhibit 5                      
HARVARD BIOSCIENCE, INC.
Reconciliation of GAAP Net (Loss) Income to Non-GAAP Adjusted Net Income
(unaudited, in thousands)
                       
                       
    Three Months Ended     Six Months Ended
    June 30,     June 30,
      2016         2015         2016         2015  
                       
GAAP net (loss) income $   (713 )   $   349     $   (1,349 )   $   (1,052 )
                       
Adjustments:                      
                       
Amortization of intangible assets     690         678         1,370         1,471  
                       
Inventory valuation step-up charges on acquisition     -         402         -         793  
                       
Forensic investigation costs     498         -         1,663         -  
                       
Severance and restructuring charges     1         437         12         783  
                       
Acquisition costs     -         198         6         781  
                       
Stock-based compensation expense     899         692         1,653         1,272  
                       
Income taxes (A)     (386 )       (1,175 )       (799 )       (1,711 )
                       
Non-GAAP adjusted net income $   989     $   1,581     $   2,556     $   2,337  
                       
(A)  Income taxes includes the tax effect of adjusting for the reconciling items.
 
Exhibit 6                    
HARVARD BIOSCIENCE, INC.
Reconciliation of GAAP Diluted (Loss) Earnings Per Common Share to Non-GAAP Adjusted Diluted Earnings Per Common Share
(unaudited)
                     
  Three Months Ended     Six Months Ended
  June 30,     June 30,
    2016         2015         2016         2015  
                     
GAAP diluted (loss) earnings per common share $ (0.02 )     $ 0.01       $ (0.04 )     $ (0.03 )
                     
Adjustments:                    
                     
Amortization of intangible assets   0.02         0.02         0.04         0.05  
                     
Inventory valuation step-up charges on acquisition   -         0.01         -         0.02  
                     
Forensic investigation costs   0.01         -         0.05         -  
                     
Severance and restructuring charges   -         0.01         -         0.02  
                     
Acquisition costs   -         0.01         -         0.02  
                     
Stock-based compensation expense   0.03         0.02         0.05         0.04  
                     
Income taxes  (A)   (0.01 )       (0.03 )       (0.02 )       (0.05 )
                     
Non-GAAP adjusted diluted earnings per common share $ 0.03       $ 0.05       $ 0.08       $ 0.07  
                     
(A)  Income taxes includes the tax effect of adjusting for the reconciling items.
Exhibit 7          
HARVARD BIOSCIENCE, INC.
Reconciliation of Guidance for 2016 GAAP Diluted Earnings per Common Share to Non-GAAP Adjusted Diluted Earnings per Common Share
(unaudited)
           
       
GAAP diluted earnings per common share (A)   $   0.00 - 0.02      
           
Adjustments:          
           
Amortization of intangible assets       0.08      
           
Forensic investigation costs       0.05      
           
Stock-based compensation expense       0.09      
           
Income taxes (B)       (0.06 )    
           
Non-GAAP adjusted diluted earnings per common share (A)   $   0.16 - 0.18      
           
(A)  This guidance excludes the impact of future acquisitions, acquisition costs or restructuring charges.  
   
(B)  Income taxes includes the tax effect of adjusting for the reconciling items.